Table. IDFS and DRFS Based on Tumor Size in Patients Who Received NAC.
| Characteristic | IDFS | DRFS | ||||
|---|---|---|---|---|---|---|
| Abemaciclib + ET | ET alone | HR (95% CI) | Abemaciclib + ET | ET alone | HR (95% CI) | |
| Residual pathological tumor size at surgery (post NAC) | ||||||
| ≤2 cm | NA | NA | 0.56 (0.34-0.90) | NA | NA | 0.48 (0.28-0.83) |
| Patients, No. | 405 | 413 | NA | 405 | 413 | NA |
| Events, No. | 26 | 46 | NA | 19 | 39 | NA |
| 2-Year rates | 91.4 | 82.2 | NA | 93.7 | 84.4 | NA |
| >2 cm | NA | NA | 0.61 (0.44-0.84) | NA | NA | 0.64 (0.45-0.90) |
| Patients, No. | 569 | 575 | NA | 569 | 575 | NA |
| Events, No. | 59 | 97 | NA | 52 | 82 | NA |
| 2-Year rates | 85 | 79 | NA | 87.4 | 81.2 | NA |
| No. of positive nodes assessed at surgery (post NAC)a | ||||||
| 1-3 | NA | NA | 0.73 (0.43-1.23) | NA | NA | 0.76 (0.44-1.33) |
| Patients, No. | 334 | 340 | NA | 334 | 340 | NA |
| Events, No. | 24 | 33 | NA | 22 | 29 | NA |
| 2-Year rates | 90.8 | 87.6 | NA | 92.1 | 89 | NA |
| ≥4 | NA | NA | 0.57 (0.41-0.81) | NA | NA | 0.57 (0.39-0.83) |
| Patients, No. | 521 | 516 | NA | 521 | 516 | NA |
| Events, No. | 51 | 87 | NA | 42 | 73 | NA |
| 2-Year rates | 85.1 | 77.2 | NA | 87.7 | 79.7 | NA |
Abbreviations: DRFS, distant relapse-free survival; ET, endocrine therapy; HR, hazard ratio; IDFS, invasive disease-free survival; NA, not applicable; NAC, neoadjuvant chemotherapy.
a
Lymph node information after surgery was not available for all patients.